Kymera completes Phase 2b enrollment for atopic dermatitis candidate KT-621

Kymera finished enrollment early for the Phase 2b BROADEN2 trial for atopic dermatitis candidate KT-621, accelerating data timelines to year-end 2026. The early success supports the company's plan to initiate Phase 3 trials in mid-2027 following regulatory review.